Announcement
NeuroSearch A/S' share capital and voting rights
On 23 January 2008, NeuroSearch increased its share capital with the issue of
185,755 new shares of DKK 20 nominal value each at a price of DKK 319.21 each as
milestone payment to the sellers of Carlsson Research AB relating to the
start-up of the Phase I study with the drug candidate ACR343.
Pursuant to section 6 of Executive Order no. 1172 of 9 October 2007 on Issuers'
Disclosure Obligations, it is hereby announced that at the end of January 2008,
the total nominal value of NeuroSearch A/S' share capital is DKK 308,568,840,
which is made up of 15,428,442 shares with a nominal value of DKK 20 each, and
corresponding to 308,568,840 votes.
Asger Aamund
Chairman of the Board
Contact persons:
Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4017 5103
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of the company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in
partnership with GSK, NS1209 in epilepsy/pain (Phase II), ABT-894 in ADHD (Phase
II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia
(Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's
disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS
diseases - both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o.
(Phase I) in partnership with GSK and ACR343 in Parkinson's disease (Phase I).
In addition, NeuroSearch has a broad portfolio of preclinical drug candidates
and holds equity interests in several biotech companies.
